Maytansine
Based on 1 Customer Validation
Maytansine is a highly potent microtubule-targeted compound that induces mitotic arrest and kills tumor cells at subnanomolar concentrations.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.81%
- No. CAS: 35846-53-8
- Fòrmula: C34H46ClN3O10
- Peso molecular:692.20
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-15162
Monomethyl auristatin EAntimitotic Agent -
HY-19792
MertansineMicrotubule-Targeted Cytotoxin -
HY-16569
ColchicineTubulin Inhibitor -
HY-15579
MMAFTubulin Inhibitor -
HY-13780
Vinblastine sulfatenAChR Inhibitor -
HY-14949
Cevipabulin -
HY-12454
DM4Tubulin Inhibitor -
HY-13442
EribulinMicrotubule Inhibitor -
HY-13631E
DeruxtecanDrug-Linker Conjugates for ADC -
HY-12053A
Vinorelbine ditartrateAnti-mitotic Agent -
HY-15162R
Monomethyl auristatin E (Standard)Analytical Standard -
HY-136121
Tubulin inhibitor 6Tubulin Inhibitor
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
0.74 nM
Compound: Maytansine
|
Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38294341] |
| A-375 | IC50 |
0.037 nM
Compound: 1
|
Cytotoxicity against human A375 cell line by clonogenic plating efficiency assay after 72 hrs
Cytotoxicity against human A375 cell line by clonogenic plating efficiency assay after 72 hrs
|
[PMID: 16821799] |
| A-431 | IC50 |
0.04 nM
Compound: 1
|
Cytotoxicity against human A431 cell line by clonogenic plating efficiency assay after 72 hrs
Cytotoxicity against human A431 cell line by clonogenic plating efficiency assay after 72 hrs
|
[PMID: 16821799] |
| A549 | IC50 |
0.16 nM
Compound: 1
|
Cytotoxicity against human A549 cell line by clonogenic plating efficiency assay after 72 hrs
Cytotoxicity against human A549 cell line by clonogenic plating efficiency assay after 72 hrs
|
[PMID: 16821799] |
| A549 | IC50 |
0.59 nM
Compound: Maytansine
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38294341] |
| HCT-15 | IC50 |
0.75 nM
Compound: 1
|
Cytotoxicity against human HCT15 cell line by clonogenic plating efficiency assay after 72 hrs
Cytotoxicity against human HCT15 cell line by clonogenic plating efficiency assay after 72 hrs
|
[PMID: 16821799] |
| HeLa | IC50 |
0.33 nM
Compound: Maytansine
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38294341] |
| HeLa | IC50 |
1.1 nM
Compound: Maytansine
|
Antiproliferative activity against human HeLa cells expressing tubulin betaIII assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells expressing tubulin betaIII assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38294341] |
| KB | ED50 |
0.0000061 μg/mL
Compound: 1
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 563462] |
| KB | ED50 |
0.51 μg/mL
Compound: Maytansine
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 7130986] |
| KB | IC50 |
0.034 nM
Compound: 1
|
Cytotoxicity against human KB cell line by clonogenic plating efficiency assay after 72 hrs
Cytotoxicity against human KB cell line by clonogenic plating efficiency assay after 72 hrs
|
[PMID: 16821799] |
| MCF7 | IC50 |
0.044 nM
Compound: 1
|
Cytotoxicity against human MCF7 cell line by clonogenic plating efficiency assay after 72 hrs
Cytotoxicity against human MCF7 cell line by clonogenic plating efficiency assay after 72 hrs
|
[PMID: 16821799] |
| OVCAR-3 | IC50 |
0.1 nM
Compound: 1
|
Cytotoxicity against human Ovcar3 cell line by clonogenic plating efficiency assay after 72 hrs
Cytotoxicity against human Ovcar3 cell line by clonogenic plating efficiency assay after 72 hrs
|
[PMID: 16821799] |
| SK-BR-3 | IC50 |
0.03 nM
Compound: 1
|
Cytotoxicity against human SK-Br-3 cell line by clonogenic plating efficiency assay after 72 hrs
Cytotoxicity against human SK-Br-3 cell line by clonogenic plating efficiency assay after 72 hrs
|
[PMID: 16821799] |
| SW-620 | IC50 |
>0.1 nM
Compound: 1
|
Cytotoxicity against human SW620 cell line by clonogenic plating efficiency assay after 72 hrs
Cytotoxicity against human SW620 cell line by clonogenic plating efficiency assay after 72 hrs
|
[PMID: 16821799] |
In Vitro
Maytansine, at 6x10-8 M, irreversibly inhibits cell division in eggs of sea urchins and clams. Maytansine causes the disappearance of a mitotic apparatus or prevents one from forming if added at early stages. Maytansine inhibits in vitro polymerization of tubulin[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
Chemical Information
-
No. CAS 35846-53-8
-
Appearance Solid
-
Peso molecular 692.20
-
Fòrmula C34H46ClN3O10
-
Color White to off-white
-
SMILES
C[C@]12[C@@]([C@@H]([C@]3([H])C[C@]([C@@H](/C=C/C=C(CC4=CC(N(C(C[C@@H]2OC([C@H](C)N(C)C(C)=O)=O)=O)C)=C(C(OC)=C4)Cl)\C)OC)(NC(O3)=O)O)C)([H])O1
-
Synonyms
NSC 153858
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
In Vitro:
DMSO : 100 mg/mL (144.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.61 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.61 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Lopus M, et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther. 2010;9(10):2689-2699. [Content Brief]
[2]. Remillard S, et al. Antimitotic activity of the potent tumor inhibitor maytansine. Science. 1975;189(4207):1002-1005. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4447 mL | 7.2233 mL | 14.4467 mL | 36.1167 mL |
| 5 mM | 0.2889 mL | 1.4447 mL | 2.8893 mL | 7.2233 mL | |
| 10 mM | 0.1445 mL | 0.7223 mL | 1.4447 mL | 3.6117 mL | |
| 15 mM | 0.0963 mL | 0.4816 mL | 0.9631 mL | 2.4078 mL | |
| 20 mM | 0.0722 mL | 0.3612 mL | 0.7223 mL | 1.8058 mL | |
| 25 mM | 0.0578 mL | 0.2889 mL | 0.5779 mL | 1.4447 mL | |
| 30 mM | 0.0482 mL | 0.2408 mL | 0.4816 mL | 1.2039 mL | |
| 40 mM | 0.0361 mL | 0.1806 mL | 0.3612 mL | 0.9029 mL | |
| 50 mM | 0.0289 mL | 0.1445 mL | 0.2889 mL | 0.7223 mL | |
| 60 mM | 0.0241 mL | 0.1204 mL | 0.2408 mL | 0.6019 mL | |
| 80 mM | 0.0181 mL | 0.0903 mL | 0.1806 mL | 0.4515 mL | |
| 100 mM | 0.0144 mL | 0.0722 mL | 0.1445 mL | 0.3612 mL |
Maytansine Related Classifications
HY-13674 Related Classifications
Powered by Bioz